Ethris is a Munich-based clinical-stage biotechnology company developing RNA therapeutics and vaccines for respiratory diseases. Its proprietary SNIM RNA and SNaP LNP platforms deliver stabilized mRNA directly to the respiratory tract via inhalation or nasal spray, with lead candidate ETH47 encoding interferon lambda.
1
Round
1
Industry
3
Tags
Sep 10, 2026
Latest raise
Funding activity · 1 round
Sep 10, 2026
EUR 30M
Debt
Led by European Investment Bank
Ethris Secures €30M Debt Financing Munich based clinical stage biotechnology company Ethris has raised €30 million in debt financing, according to funding data…
Read articlePricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
